U.S. flag An official website of the United States government
  1. Home
  2. Drug Databases
  3. Drug Shortages

FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

The FDA Drug Shortage database is currently experiencing technical difficulties and some of the information contained in the database may not reflect the current supply status.

Start Over | Back to Search Results

Dacarbazine Injection
Status: Currently in Shortage
»Date first posted: 10/20/2021
»Therapeutic Categories: Oncology

Expand all

Fresenius Kabi USA, LLC (Reverified 08/12/2022)

Company Contact Information:
888-386-1300

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
100 mg per vial, Single Dose Amber Vial (NDC 63323-127-10) Available Manufacturing delay
200 mg per vial, Single Dose Amber Vial (NDC 63323-128-20) Available Manufacturing delay

Hikma Pharmaceuticals USA, Inc. (formerly West-Ward) (Reverified 04/08/2022)

Company Contact Information:
800-631-2174

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
200 mg/vial (NDC 0143-9245-10) Inventory is currently available. Demand increase for the drug

Teva Pharmaceuticals (Reverified 07/01/2022)

Company Contact Information:
800-545-8800

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
200 mg 10x20mL (NDC 00703-5075-03) Backordered – Est date of availability TBD Demand increase for the drug
200 mg 1x20mL (NDC 00703-5075-01) Backordered – Est date of availability TBD Demand increase for the drug
Back to Top